Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...
Read Full NewsA phase 2a trial showed that NLX-112 was safe and well tolerated in patients with Parkinson disease, while also reducing levodopa-induced dyskinesia and motor symptoms, supporting further clinical development.
AskBio noted that AB-1009 also recently received fast track and orphan drug designations from the FDA.
Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older
1.
Health of Myeloma Patient's Marriage Tied to Recovery After Transplant
2.
GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.
3.
In cases of locally advanced, potentially curable pancreatic cancer, a combination of drugs enhances the results of radiation therapy.
4.
New imaging solution could help improve survival for patients with recurring prostate cancer
5.
An understudied type of breast cancer poses a lurking threat
1.
Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice
2.
From Bench to Bedside: The New Era of Lymphoma Treatment and Education
3.
The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review
4.
Understanding Lymphedema: Symptoms, Causes, and Treatment
5.
Gene Therapy for Hemophilia: A New Hope on the Horizon
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Efficient Management of First line ALK-rearranged NSCLC - Part V
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
5.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge